1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor typesXiaochen Zhao,Jun Shen,Mathangi Gopalakrishnan,Yan Feng,B J Schmidt,Paul Statkevich, T Kelleher, M Rashford,Vijay Ivaturi,Joga Gobburu,Shruti Agrawal,Akintunde Bello,Amit RoyANNALS OF ONCOLOGY(2018)引用 3|浏览8暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要